Kanthasamy A G, Vu T Q, Yun R J, Truong D D
Department of Neurology, College of Medicine, University of California Irvine 92717, USA.
Eur J Pharmacol. 1996 Feb 22;297(3):219-24. doi: 10.1016/0014-2999(95)00741-5.
The antimyoclonic property of the novel antiepileptic drug, gabapentin (1-(aminomethyl) cyclohexane acetic acid), was tested in cardiac arrest-and p,p'-DDT(1,1,1-trichloro-2,2-bis (p-chlorophenyl)ethane)-induced animal models of myoclonus. Gabapentin dose-dependently attenuated myoclonus in posthypoxic rats for more than 3 h. The drug was also found to be effective in controlling the early stages of seizures following the anoxic insult. In contrast, the drug was ineffective in controlling either myoclonus or seizures in p,p'-DDT-treated animals. These results suggest that gabapentin can be used used as an effective therapeutic agent in an acute hypoxia/ischemia-induced neurological disorder. The data further indicate that distinct neurological mechanisms may be operating in the expression of myoclonus among posthypoxic and p,p'-DDT-induced animal models.
新型抗癫痫药物加巴喷丁(1-(氨基甲基)环己烷乙酸)的抗肌阵挛特性在心脏骤停和对硫磷(1,1,1-三氯-2,2-双(对氯苯基)乙烷)诱导的肌阵挛动物模型中进行了测试。加巴喷丁在缺氧后大鼠中剂量依赖性地减轻肌阵挛超过3小时。还发现该药物在控制缺氧损伤后的癫痫发作早期有效。相比之下,该药物在控制对硫磷治疗的动物的肌阵挛或癫痫发作方面无效。这些结果表明,加巴喷丁可作为急性缺氧/缺血性神经疾病的有效治疗剂。数据进一步表明,在缺氧后和对硫磷诱导的动物模型中,肌阵挛表达可能存在不同的神经机制。